Health Canada Implements ICH Pharmaceutical Guidelines

Detected March 13th, 2026

Summary

Health Canada is implementing new International Council for Harmonisation (ICH) guidelines for pharmaceuticals, including M13A and Q12/Q14. These implemented ICH guidelines will take precedence over existing Health Canada guidance documents where discrepancies exist, potentially leading to amendments or withdrawals of current guidance.

View original document View source feed page

What changed

Health Canada has announced the implementation of several International Council for Harmonisation (ICH) guidelines, including M13A (Bioequivalence for Immediate-Release Solid Oral Dosage Forms) and Q12/Q14 (Pharmaceutical Product Lifecycle Management and Analytical Procedure Development). These implemented guidelines will take precedence over existing Health Canada guidance documents where inconsistencies are found. This initiative is part of Canada's commitment to international harmonisation in pharmaceutical regulation.

Pharmaceutical manufacturers and related entities must be aware that these new ICH guidelines will supersede conflicting Health Canada guidance. Health Canada will publish explanatory notices and may amend or withdraw existing guidance documents to align with the ICH standards. Companies should review their current practices and documentation to ensure compliance with the newly implemented ICH guidelines, particularly concerning bioequivalence and product lifecycle management. Specific implementation dates are noted as December 27, 2025, for M13A and January 12, 2026, for Q12/Q14.

What to do next

Review implemented ICH guidelines M13A, Q12, and Q14 for impact on current practices.
Identify and address any discrepancies between existing Health Canada guidance and the new ICH guidelines.
Monitor for forthcoming explanatory notices from Health Canada regarding amendments or withdrawals of existing guidance documents.

Source document (simplified)

International Council for Harmonisation (ICH)

Guidelines: (Efficacy, Multidisciplinary, Quality, Safety)

Information on ICH guidelines implemented by Health Canada

The tables below outline the International Council for Harmonisation of Technical Requirements of Pharmaceuticals for Human Use (ICH) guideline(s) implemented by Health Canada. These guidelines have been developed by the appropriate ICH Expert Working Groups and have been subject to consultation by the regulatory parties, in accordance with the ICH Process. The ICH Assembly has endorsed the final draft and recommended its implementation by the membership of ICH.

In implementing these ICH guidelines, Health Canada endorses the principles and practices described therein. Please note that the ICH website is only available in English. If you would like to request a copy of the French version of the document, please contact the HPFB ICH inbox.

It is recognized that the scope and subject matter of current Health Canada guidance documents may not be entirely consistent with those of the ICH guidelines that are being introduced as part of our commitment to international harmonisation and the ICH Process. In such circumstances, Health Canada-implemented ICH guidelines take precedence.

Health Canada is committed to eliminating such discrepancies and will publish explanatory notices for stakeholders, where applicable. This will result in the amendment or, depending on the extent of revisions required, withdrawal of some Health Canada guidance documents.

Should you have any questions or comments regarding the contents of the ICH guidelines, please contact:

Health Canada - ICH Coordinator
E-mail: ich@hc-sc.gc.ca

Recently finalised ICH guidelines

This table lists ICH guidelines that have recently been finalised at ICH and are either pending implementation or have been implemented by Health Canada in the last 12 months

| Document | Type of Notice | File Number | Additional Notes |
| --- | --- | --- | --- |
| M13A Implementation: Bioequivalence for Immediate-Release Solid Oral Dosage Forms | Notice | 25-102237-854 | This guideline was implemented on December 27, 2025 |
| Q12: Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management | Notice | 25-105890 – 674 | Interim implementation January 12, 2026. |
| Q14: Analytical Procedure Development | Notice | 25-105890 – 674 | This guideline was implemented on January 12, 2026 |
| M14: General Principles on Planning, Designing, Analyzing, and Reporting of Non-interventional Studies That Utilize Real-World Data for Safety Assessment of Medicines | Step 4 - Final Guideline | 25-108149 - 635 | This guideline was implemented on January 12, 2026 |
| E2D(R1): Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting | Step 4 - Final Guideline | 25-108149 - 635 | This guideline was implemented on January 12, 2026 |
| E6(R3): Good Clinical Practice | Notice | 25-105890 – 674 | Implementation targeted April 1, 2026. |
| E11A: Paediatric Extrapolation | Step 4 - Final Guideline | 25-105890 – 674 | This guideline was implemented on October 17, 2025 |
| Q2(R2): Revision to Analytical Validation | Step 4 - Final Guideline | 25-105890 – 674 | This guideline was implemented on October 17, 2025 |
| Q13: Continuous Manufacturing of Drug Substances and Drug Products | Step 4 - Final Guideline | 25-102237-854 | This guideline was implemented on June 27, 2025 |
| Q5A(R2): Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin | Step 4 - Final Guideline | 25-102237-854 | This guideline was implemented on June 27, 2025 |
| Q3C(R9): Impurities: Residual Solvents | Step 4 - Final Guideline | 25-102237-854 | This guideline was implemented on June 27, 2025 |